Spyros Triantos

987 total citations · 1 hit paper
49 papers, 390 citations indexed

About

Spyros Triantos is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Spyros Triantos has authored 49 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 28 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Spyros Triantos's work include Bladder and Urothelial Cancer Treatments (26 papers), Fibroblast Growth Factor Research (22 papers) and Urinary and Genital Oncology Studies (14 papers). Spyros Triantos is often cited by papers focused on Bladder and Urothelial Cancer Treatments (26 papers), Fibroblast Growth Factor Research (22 papers) and Urinary and Genital Oncology Studies (14 papers). Spyros Triantos collaborates with scholars based in United States, France and United Kingdom. Spyros Triantos's co-authors include Yohann Loriot, Arlene O. Siefker‐Radtke, Sydney Akapame, Se Hoon Park, Earle F. Burgess, Robert Huddart, Valentina Guadalupi, Kris Deprince, Séverine Banek and Nadine Houédé and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Spyros Triantos

40 papers receiving 388 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. profile →

Peers

Countries citing papers authored by Spyros Triantos

Since Specialization

Citations

This map shows the geographic impact of Spyros Triantos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Spyros Triantos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Spyros Triantos more than expected).

Fields of papers citing papers by Spyros Triantos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Spyros Triantos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Spyros Triantos. The network helps show where Spyros Triantos may publish in the future.

Co-authorship network of co-authors of Spyros Triantos

This figure shows the co-authorship network connecting the top 25 collaborators of Spyros Triantos. A scholar is included among the top collaborators of Spyros Triantos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Spyros Triantos. Spyros Triantos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER 2025 ·Urologic Oncology Seminars and Original Investigations ·Roger Li, Gautam Jayram, Angela Girvin, Anne Marie O’Hagan, Sabine Brookman‐May, (unknown), Nicole L. Stone, (unknown), (unknown), (unknown), Neil Beeharry, Spyros Triantos, Benjamin Pradere	0
2	Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study 2025 ·Clinical Genitourinary Cancer ·Nobuaki Matsubara, Yohann Loriot, Earle F. Burgess, Se Hoon Park, Robert Huddart, Ja Hyeon Ku, Ben Tran, Jian Huang, Yu‐An Huang, Kazuo Nishimura, Nobuaki Shimizu, (unknown), Wei Xue, (unknown), (unknown), (unknown), Spyros Triantos, Arlene O. Siefker‐Radtke	1
3	Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 2025 ·European Urology ·Siamak Daneshmand, Renata Zaucha, James W.F. Catto, Ben Tran, Viraj A. Master, (unknown), G. Pignot, Andrea Tubaro, Nobuaki Shimizu, Nikhil Vasdev, Eugene K. Lee, Giuseppe Procopio, (unknown), (unknown), Kris Deprince, Vahid Naini, Spyros Triantos, Mahadi Baig, Wei Zhu, Jodi K. Maranchie	0
4	MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS 2024 ·Urologic Oncology Seminars and Original Investigations ·Siamak Daneshmand, Renata Zaucha, Nikhil Vasdev, Benjamin A. Gartrell, Yair Lotan, Syed A. Hussain, Eugene K. Lee, Giuseppe Procopio, (unknown), G. Pignot, Debasish Sundi, (unknown), (unknown), Vahid Naini, Spyros Triantos, Mahadi Baig, Jodi K. Maranchie	1
5	FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro). 2024 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert Huddart, Earle F. Burgess, (unknown), Neil Beeharry, Shibu Thomas, Nicole L. Stone, Kris Deprince, Spyros Triantos, Woonyoung Choi	0
6	Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies. 2024 ·Journal of Clinical Oncology ·Shubham Pant, Joon Oh Park, Wu‐Chou Su, Martin Schüler, (unknown), Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Gunnar Folprecht, Helen Winter, Graziela Zibetti Dal Molin, Hussein Sweiti, (unknown), Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin‐Hsun Feng	1
7	Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations 2024 ·International Journal of Clinical Oncology ·Nobuaki Matsubara, Yuji Miura, Hiroyuki Nishiyama, (unknown), (unknown), Nobuaki Shimizu, Jason Hwang, (unknown), (unknown), Kiichiro Toyoizumi, Sutapa Mukhopadhyay, Spyros Triantos, Kris Deprince, Yohann Loriot	3
8	Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial 2024 ·BMC Cancer ·Joon Oh Park, Yin‐Hsun Feng, Wu‐Chou Su, Do‐Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, (unknown), Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, (unknown), Liming Peng, Spyros Triantos, Hussein Sweiti	9
9	Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma 2024 ·Journal of health economics and outcomes research ·Suzy Van Sanden, (unknown), (unknown), (unknown), Spyros Triantos, (unknown), Caitlin Daly	1
10	1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial 2023 ·Annals of Oncology ·Shubham Pant, Dirk Arnold, Josep Tabernero, Yohann Loriot, Gunnar Folprecht, Georg Martin Haag, Daniel H. Palmer, Hans Prenen, Jermaine Coward, Iwona Ługowska, (unknown), Andrés Cervantes, Martin Gutierrez, Hussein Sweiti, Constance Hammond, (unknown), Shibu Thomas, Spyros Triantos, (unknown), (unknown)	2
11	CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL 2023 ·Neuro-Oncology ·David A. Reardon, Liam Welsh, Kent C. Shih, Toshio Shimizu, Jean‐Charles Goeminne, Birgit Geoerger, Capucine Baldini, Christophe Massard, Yohann Loriot, Shubham Pant, Sameer Farouk Sait, Shibu Thomas, Constance Hammond, (unknown), Spyros Triantos, (unknown), Hussein Sweiti, Olaf Witt	0
12	192P Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting 2023 ·Annals of Oncology ·Hussein Sweiti, (unknown), Spyros Triantos, (unknown), Shibu Thomas, Joel Greshock, (unknown), (unknown), Paige Sheridan, Shubham Pant, Christophe Massard, David A. Reardon, Yohann Loriot, (unknown)	0
13	2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study 2023 ·Annals of Oncology ·Yohann Loriot, Nobuaki Matsubara, Robert Huddart, Nadine Houédé, Brigitte Laguerre, Valentina Guadalupi, Ja Hyeon Ku, Spyros Triantos, Sydney Akapame, Kris Deprince, Saikat Mukhopadhyay, Arlene O. Siefker‐Radtke	1
14	Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study 2022 ·European Urology Open Science ·Arash Rezazadeh Kalebasty, David J. Benjamin, Yohann Loriot, (unknown), Arlene O. Siefker‐Radtke, Andrea Necchi, Vahid Naini, (unknown), Ademi Santiago-Walker, Spyros Triantos, Earle F. Burgess	4
15	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer 2021 ·Cancer Medicine ·Robin L. Jones, Thomas J. Herzog, Shreyaskumar Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland E. Knoblauch, Spyros Triantos, Peter Hu, Waleed S.W. Shalaby, Tracy McGowan, Bradley J. Monk, George D. Demetri	10
16	LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study 2021 ·Annals of Oncology ·Thomas Powles, (unknown), (unknown), Andrey Semenov, Els Everaert, (unknown), Víctor Moreno, Begoña P. Valderrama, Yann Vano, (unknown), Yohann Loriot, Taek Won Kang, (unknown), Anne O’Hagan, Maryam Hosseini, Spyros Triantos, Harleen Chhabra, (unknown), Arlene O. Siefker‐Radtke	12
17	Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia 2021 ·Asian Journal of Andrology ·Byung Ha Chung, Jian Huang, Zhangqun Ye, Dalin He, (unknown), Gaku Arai, Choung‐Soo Kim, (unknown), (unknown), Seokhyeon Jeong, Suneel Mundle, Spyros Triantos, Sharon McCarthy, Kim N., Dingwei Ye	11
18	Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer 2020 ·SHILAP Revista de lepidopterología ·Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, (unknown), Roland E. Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman	3
19	A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer 2020 ·Gynecologic Oncology ·Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, (unknown), Roland E. Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman	31
20	OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 2018 ·Journal of Thoracic Oncology ·K. Park, Myung‐Ju Ahn, (unknown), (unknown), Min Hee Hong, Dawn Millington, (unknown), Spyros Triantos, Sandra R. Chaplan, Nahor Haddish‐Berhane, Roland E. Knoblauch, Zuleima Aguilar, Sylvie Laquerre, Matthew V. Lorenzi, B.C. Cho	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact